BioPharma Dive· Jonathan Gardner·· 6 hours agoScore70
Merck KGaA bets on RNAi with $1.3B Silence buyout
In brief
Merck KGaA announced on October 19, 2026 that it will acquire UK-based Silence Therapeutics for approximately $1.3 billion, paying $20 in cash per U.S.-listed share, a 130% premium. Key shareholders representing 14% of voting power have agreed, and the company expects the deal to close in the first quarter of 2027.
Source: BioPharma Dive · biopharmadive.com